2026 Q2 -tulosraportti
36 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,01%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 173 | DDB | DDB | ||
| 171 | - | - | ||
| 170 | - | - | ||
| 341 | - | - | ||
| 25 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5 t sittenWhy it might be a bad idea to sell Novo Nordisk now Novo Nordisk has undoubtedly been severely punished on the stock market. The price drop has created great uncertainty among investors, and competition in the obesity market has become much tougher. But precisely for this reason, it may be worth considering whether it really is the right time to sell. Firstly, Novo is still one of the world's strongest companies in diabetes and obesity. Wegovy and Ozempic have already created an enormous market, and Novo is simultaneously working on the next generation of treatments. The company has, among other things, Wegovy in tablet form, higher-dose Wegovy, and CagriSema in the pipeline. (Novo Nordisk) This is important because the stock market often looks very far ahead. If Novo succeeds in widely launching new products on the market, the current share price may prove to have already factored in much of the negative sentiment. Secondly, Novo is not just a story about current Wegovy sales. The company's pipeline extends far beyond a single product. Novo continues to have several obesity treatments in clinical studies, including cagrilintide and zenagamtide, while CagriSema has already been submitted for US approval. (Novo Nordisk) An interesting positive signal has also emerged very recently: Novo's STEP Young study showed that 40.4 % of the children in the trial after 68 weeks were no longer classified as having obesity. This potentially opens up another large treatment area for semaglutide. (Reuters) Thirdly, it can be dangerous to sell after a large price drop. When a stock has already fallen sharply, the question is no longer what you bought it for. The question is whether its future value is higher or lower than today's price. If Novo, for example, again starts to deliver better than the market expects, the share price can react positively quickly. The investor who sells just before such a turnaround risks being on the sidelines while the stock rises. However, there are also real problems. Novo has lost some of its previous growth luster, competition from Eli Lilly is tough, and CagriSema has previously disappointed in a head-to-head trial against Lilly's tirzepatid. (Novo Nordisk) Furthermore, Novo recently stopped further trials with ziltivekimab after disappointing results, which shows that pipeline risk is real. (Reuters) But precisely for this reason, I think the interesting point is: You don't have to believe that Novo will return to old highs to argue for holding the stock. You just need to believe that the market today undervalues the company's long-term opportunities. Novo will also hold a Capital Markets Day on 21. September 2026, where management will present strategy, pipeline, business, and future opportunities. This could be an important event for investors. (Novo Nordisk) Conclusion I would therefore be cautious about selling Novo just because the price has fallen a lot. A large price drop does not automatically mean that the company has become bad. Novo still has an enormous global business, strong products, a significant pipeline, and the opportunity to create new growth areas. If one has a long time horizon, it may therefore make more sense to give Novo time to prove that the market has been too pessimistic, rather than selling at a time when sentiment around the stock is very negative. The biggest risk of holding Novo is, of course, that the price could fall further. But the biggest risk of selling now could be selling after the big downturn – just before the market again begins to focus on Novo's long-term potential. 📈
·6 t sittenI guess we will go down to price 250 by Christmas, my guess ughhhhh
·6 t sitten · MuokattuSo, someone is driving the price down on almost no volume currently. I have attached both today's and graphs showing average daily volume for the last year, 3 years, 5 years etc. for comparison. Note. what the graph shows as today in (fig.2) is yesterday's closing volume. Today it is only approx. half as large so far!!
Price 286. Now be careful with her totally irrelevant talk about volume. It is COMPLETELY without significance. It is a very vague attempt to make you believe that then a price drop doesn't mean anything. She never comes with any concrete fundamental knowledge about Novo in here. It's all about what she can see from coffee grounds.
·6 t sittenArguments for waiting (The cautious investor / Trader)Technical headwinds and sell signals: Looking at the stock's technical momentum, the picture is weak. Analysis houses like Investtech and platforms like TradeDesk have triggered short-term sell and hold signals. The price has broken important support levels, and technically, the stock risks falling further towards the next support level around 270 DKK. [1] (https://tradedesk.dk/stock/novo-b.co#:~:text=Novo%20Nordisk%20%28NOVO%2DB%29,selv%20om%20aktien%20passer)Price pressure in the USA: The American Trump administration has entered into price agreements on obesity medication for 2026, which pressures Novo's advances and margins. [1] (https://global.morningstar.com/en-nd/stocks/novo-nordisk-what-we-think-stock-after-earnings#:~:text=NOVO%20B%20saw%206%25,expands.)Increased competition: Competitor Eli Lilly is stirring with new clinical data for their pill and weekly treatments, and generic (copied) medicine has already been launched in countries like Brazil and Canada.
The bid at 270, is also my possible bottom. I don't use technical analysis, but I remember the price development of the stocks I trade. Very precisely. On the way down to 230, earlier this year, it hit the 270 level a couple of times, where it rebounded to 300. 300 will not be easy for Novo to finally break.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
36 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,01%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenWhy it might be a bad idea to sell Novo Nordisk now Novo Nordisk has undoubtedly been severely punished on the stock market. The price drop has created great uncertainty among investors, and competition in the obesity market has become much tougher. But precisely for this reason, it may be worth considering whether it really is the right time to sell. Firstly, Novo is still one of the world's strongest companies in diabetes and obesity. Wegovy and Ozempic have already created an enormous market, and Novo is simultaneously working on the next generation of treatments. The company has, among other things, Wegovy in tablet form, higher-dose Wegovy, and CagriSema in the pipeline. (Novo Nordisk) This is important because the stock market often looks very far ahead. If Novo succeeds in widely launching new products on the market, the current share price may prove to have already factored in much of the negative sentiment. Secondly, Novo is not just a story about current Wegovy sales. The company's pipeline extends far beyond a single product. Novo continues to have several obesity treatments in clinical studies, including cagrilintide and zenagamtide, while CagriSema has already been submitted for US approval. (Novo Nordisk) An interesting positive signal has also emerged very recently: Novo's STEP Young study showed that 40.4 % of the children in the trial after 68 weeks were no longer classified as having obesity. This potentially opens up another large treatment area for semaglutide. (Reuters) Thirdly, it can be dangerous to sell after a large price drop. When a stock has already fallen sharply, the question is no longer what you bought it for. The question is whether its future value is higher or lower than today's price. If Novo, for example, again starts to deliver better than the market expects, the share price can react positively quickly. The investor who sells just before such a turnaround risks being on the sidelines while the stock rises. However, there are also real problems. Novo has lost some of its previous growth luster, competition from Eli Lilly is tough, and CagriSema has previously disappointed in a head-to-head trial against Lilly's tirzepatid. (Novo Nordisk) Furthermore, Novo recently stopped further trials with ziltivekimab after disappointing results, which shows that pipeline risk is real. (Reuters) But precisely for this reason, I think the interesting point is: You don't have to believe that Novo will return to old highs to argue for holding the stock. You just need to believe that the market today undervalues the company's long-term opportunities. Novo will also hold a Capital Markets Day on 21. September 2026, where management will present strategy, pipeline, business, and future opportunities. This could be an important event for investors. (Novo Nordisk) Conclusion I would therefore be cautious about selling Novo just because the price has fallen a lot. A large price drop does not automatically mean that the company has become bad. Novo still has an enormous global business, strong products, a significant pipeline, and the opportunity to create new growth areas. If one has a long time horizon, it may therefore make more sense to give Novo time to prove that the market has been too pessimistic, rather than selling at a time when sentiment around the stock is very negative. The biggest risk of holding Novo is, of course, that the price could fall further. But the biggest risk of selling now could be selling after the big downturn – just before the market again begins to focus on Novo's long-term potential. 📈
- ·6 t sittenI guess we will go down to price 250 by Christmas, my guess ughhhhh
- ·6 t sitten · MuokattuSo, someone is driving the price down on almost no volume currently. I have attached both today's and graphs showing average daily volume for the last year, 3 years, 5 years etc. for comparison. Note. what the graph shows as today in (fig.2) is yesterday's closing volume. Today it is only approx. half as large so far!!Price 286. Now be careful with her totally irrelevant talk about volume. It is COMPLETELY without significance. It is a very vague attempt to make you believe that then a price drop doesn't mean anything. She never comes with any concrete fundamental knowledge about Novo in here. It's all about what she can see from coffee grounds.
- ·6 t sittenArguments for waiting (The cautious investor / Trader)Technical headwinds and sell signals: Looking at the stock's technical momentum, the picture is weak. Analysis houses like Investtech and platforms like TradeDesk have triggered short-term sell and hold signals. The price has broken important support levels, and technically, the stock risks falling further towards the next support level around 270 DKK. [1] (https://tradedesk.dk/stock/novo-b.co#:~:text=Novo%20Nordisk%20%28NOVO%2DB%29,selv%20om%20aktien%20passer)Price pressure in the USA: The American Trump administration has entered into price agreements on obesity medication for 2026, which pressures Novo's advances and margins. [1] (https://global.morningstar.com/en-nd/stocks/novo-nordisk-what-we-think-stock-after-earnings#:~:text=NOVO%20B%20saw%206%25,expands.)Increased competition: Competitor Eli Lilly is stirring with new clinical data for their pill and weekly treatments, and generic (copied) medicine has already been launched in countries like Brazil and Canada.The bid at 270, is also my possible bottom. I don't use technical analysis, but I remember the price development of the stocks I trade. Very precisely. On the way down to 230, earlier this year, it hit the 270 level a couple of times, where it rebounded to 300. 300 will not be easy for Novo to finally break.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 173 | DDB | DDB | ||
| 171 | - | - | ||
| 170 | - | - | ||
| 341 | - | - | ||
| 25 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
36 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
4,01%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenWhy it might be a bad idea to sell Novo Nordisk now Novo Nordisk has undoubtedly been severely punished on the stock market. The price drop has created great uncertainty among investors, and competition in the obesity market has become much tougher. But precisely for this reason, it may be worth considering whether it really is the right time to sell. Firstly, Novo is still one of the world's strongest companies in diabetes and obesity. Wegovy and Ozempic have already created an enormous market, and Novo is simultaneously working on the next generation of treatments. The company has, among other things, Wegovy in tablet form, higher-dose Wegovy, and CagriSema in the pipeline. (Novo Nordisk) This is important because the stock market often looks very far ahead. If Novo succeeds in widely launching new products on the market, the current share price may prove to have already factored in much of the negative sentiment. Secondly, Novo is not just a story about current Wegovy sales. The company's pipeline extends far beyond a single product. Novo continues to have several obesity treatments in clinical studies, including cagrilintide and zenagamtide, while CagriSema has already been submitted for US approval. (Novo Nordisk) An interesting positive signal has also emerged very recently: Novo's STEP Young study showed that 40.4 % of the children in the trial after 68 weeks were no longer classified as having obesity. This potentially opens up another large treatment area for semaglutide. (Reuters) Thirdly, it can be dangerous to sell after a large price drop. When a stock has already fallen sharply, the question is no longer what you bought it for. The question is whether its future value is higher or lower than today's price. If Novo, for example, again starts to deliver better than the market expects, the share price can react positively quickly. The investor who sells just before such a turnaround risks being on the sidelines while the stock rises. However, there are also real problems. Novo has lost some of its previous growth luster, competition from Eli Lilly is tough, and CagriSema has previously disappointed in a head-to-head trial against Lilly's tirzepatid. (Novo Nordisk) Furthermore, Novo recently stopped further trials with ziltivekimab after disappointing results, which shows that pipeline risk is real. (Reuters) But precisely for this reason, I think the interesting point is: You don't have to believe that Novo will return to old highs to argue for holding the stock. You just need to believe that the market today undervalues the company's long-term opportunities. Novo will also hold a Capital Markets Day on 21. September 2026, where management will present strategy, pipeline, business, and future opportunities. This could be an important event for investors. (Novo Nordisk) Conclusion I would therefore be cautious about selling Novo just because the price has fallen a lot. A large price drop does not automatically mean that the company has become bad. Novo still has an enormous global business, strong products, a significant pipeline, and the opportunity to create new growth areas. If one has a long time horizon, it may therefore make more sense to give Novo time to prove that the market has been too pessimistic, rather than selling at a time when sentiment around the stock is very negative. The biggest risk of holding Novo is, of course, that the price could fall further. But the biggest risk of selling now could be selling after the big downturn – just before the market again begins to focus on Novo's long-term potential. 📈
- ·6 t sittenI guess we will go down to price 250 by Christmas, my guess ughhhhh
- ·6 t sitten · MuokattuSo, someone is driving the price down on almost no volume currently. I have attached both today's and graphs showing average daily volume for the last year, 3 years, 5 years etc. for comparison. Note. what the graph shows as today in (fig.2) is yesterday's closing volume. Today it is only approx. half as large so far!!Price 286. Now be careful with her totally irrelevant talk about volume. It is COMPLETELY without significance. It is a very vague attempt to make you believe that then a price drop doesn't mean anything. She never comes with any concrete fundamental knowledge about Novo in here. It's all about what she can see from coffee grounds.
- ·6 t sittenArguments for waiting (The cautious investor / Trader)Technical headwinds and sell signals: Looking at the stock's technical momentum, the picture is weak. Analysis houses like Investtech and platforms like TradeDesk have triggered short-term sell and hold signals. The price has broken important support levels, and technically, the stock risks falling further towards the next support level around 270 DKK. [1] (https://tradedesk.dk/stock/novo-b.co#:~:text=Novo%20Nordisk%20%28NOVO%2DB%29,selv%20om%20aktien%20passer)Price pressure in the USA: The American Trump administration has entered into price agreements on obesity medication for 2026, which pressures Novo's advances and margins. [1] (https://global.morningstar.com/en-nd/stocks/novo-nordisk-what-we-think-stock-after-earnings#:~:text=NOVO%20B%20saw%206%25,expands.)Increased competition: Competitor Eli Lilly is stirring with new clinical data for their pill and weekly treatments, and generic (copied) medicine has already been launched in countries like Brazil and Canada.The bid at 270, is also my possible bottom. I don't use technical analysis, but I remember the price development of the stocks I trade. Very precisely. On the way down to 230, earlier this year, it hit the 270 level a couple of times, where it rebounded to 300. 300 will not be easy for Novo to finally break.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 173 | DDB | DDB | ||
| 171 | - | - | ||
| 170 | - | - | ||
| 341 | - | - | ||
| 25 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt